On June 25, 2018, plaintiff KEI filed a memorandum in opposition to a motion to dismiss filed by defendants NIH et al. The opposition cites the declaration of KEI Director James Love. The original KEI complaint is here: https://www.keionline.org/27669 The… Continue Reading
(Update: The NIH provided a response to our comments on July 16, 2018) Below are comments sent by KEI, UACT and HealthGap, regarding a proposed exclusive license to Morphiex Biotherapeutics, an entity for which little is known. The license concerns… Continue Reading
On May 18, 2018 KEI requested that the Department of Health and Human Services (HHS) investigate the failure to disclose National Institutes of Health (NIH) funding in four patents on Vizamyl (INN flutemetamol F 18), which is used to evaluate… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading
1994. The 1994 NIH Report on CRADAs and the Reasonable Pricing Clause 1994. September 8. James Love. Pricing of Drugs Developed with Public Funds. Comments Presented to the Second NIH CRADA Forum. 1995. April 11. NIH Notice Rescinding the Reasonable… Continue Reading
KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading
Pages on the 2012-2013 NIH Request November 1, 2013. NIH rejects March-In petition, also rejects proposed rules on pricing of and access to government funded inventions. October 15, 2013. 15 frequently asked questions about the 2012 ritonavir March-In petition October… Continue Reading